| scholarly article | Q13442814 |
| P50 | author | Varsha Gandhi | Q63661917 |
| P2093 | author name string | Prithviraj Bose | |
| P2860 | cites work | Consistency of BRCA1 and BRCA2 Variant Classifications Among Clinical Diagnostic Laboratories | Q88695701 |
| PO-54 - Clinical and laboratory characterization of platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia | Q89401183 | ||
| Minimal residual disease is an independent predictor for 10-year survival in CLL. | Q48785580 | ||
| Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. | Q50716088 | ||
| Pathways and mechanisms of venetoclax resistance. | Q51160342 | ||
| Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. | Q51308516 | ||
| Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. | Q51682819 | ||
| NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. | Q52931736 | ||
| Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. | Q53061290 | ||
| Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. | Q53963822 | ||
| Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. | Q54316160 | ||
| Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. | Q54328623 | ||
| Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study. | Q55004285 | ||
| Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. | Q55069337 | ||
| Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions | Q56657194 | ||
| Non-coding recurrent mutations in chronic lymphocytic leukaemia | Q56996904 | ||
| Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion | Q58041703 | ||
| Cyclin-dependent kinase inhibitor therapy for hematologic malignancies | Q24561485 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 | ||
| Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor | Q27701677 | ||
| Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | Q27853011 | ||
| Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia | Q28255147 | ||
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 | ||
| Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia | Q28394721 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data | Q31096565 | ||
| Programmed anuclear cell death delimits platelet life span. | Q33374664 | ||
| Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease | Q33398808 | ||
| Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study | Q33428297 | ||
| Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study | Q33432228 | ||
| Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study | Q33438428 | ||
| Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial | Q33438825 | ||
| Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial | Q33439818 | ||
| A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab | Q33626106 | ||
| Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood | Q33774491 | ||
| Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib | Q41601558 | ||
| Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial | Q42254424 | ||
| Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. | Q42348711 | ||
| Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity | Q42401591 | ||
| The impact of SF3B1 mutations in CLL on the DNA-damage response | Q44290485 | ||
| Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells | Q46055970 | ||
| Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. | Q46731906 | ||
| Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. | Q46925495 | ||
| Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes | Q47136959 | ||
| Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia | Q33774513 | ||
| Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations | Q33814458 | ||
| Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 | ||
| Advances in treating chronic lymphocytic leukemia | Q34019917 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| SF3B1 and other novel cancer genes in chronic lymphocytic leukemia | Q34093678 | ||
| PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. | Q34106863 | ||
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 | ||
| Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study | Q34240404 | ||
| Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia | Q34402999 | ||
| Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 | ||
| IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells | Q34636880 | ||
| CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells | Q35086934 | ||
| Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK | Q35156866 | ||
| Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. | Q35250940 | ||
| Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 | ||
| Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). | Q35543223 | ||
| Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers | Q35577014 | ||
| Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia | Q35607285 | ||
| Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia | Q35615823 | ||
| Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes | Q35625192 | ||
| NOTCH1 mutations in CLL associated with trisomy 12. | Q35669190 | ||
| Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation | Q35820367 | ||
| Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia | Q35903984 | ||
| Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study | Q35953518 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia | Q36000944 | ||
| The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. | Q36021849 | ||
| Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia | Q36135185 | ||
| Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients | Q36273066 | ||
| Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | Q36490049 | ||
| Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia | Q36597026 | ||
| Evolution and impact of subclonal mutations in chronic lymphocytic leukemia | Q36619124 | ||
| Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. | Q36788133 | ||
| BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia | Q36799197 | ||
| Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia | Q36888218 | ||
| Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens | Q36900364 | ||
| Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition | Q36925503 | ||
| Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. | Q37097096 | ||
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes | Q37226729 | ||
| Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). | Q37596620 | ||
| Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib | Q37599562 | ||
| A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia | Q37609420 | ||
| Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial | Q37633475 | ||
| Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy | Q37655012 | ||
| Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia | Q37663837 | ||
| Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells | Q37725415 | ||
| Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling | Q38069567 | ||
| Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial | Q38424831 | ||
| Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells | Q38716411 | ||
| Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia | Q38732657 | ||
| The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models | Q38736457 | ||
| Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia | Q38744632 | ||
| Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States | Q38792651 | ||
| Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression | Q38794236 | ||
| Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study | Q38956893 | ||
| Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. | Q38959765 | ||
| Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib | Q38974011 | ||
| Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. | Q38978727 | ||
| Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia | Q39006397 | ||
| Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). | Q39065374 | ||
| Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. | Q39217647 | ||
| Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia | Q39226787 | ||
| Mutations driving CLL and their evolution in progression and relapse | Q39714436 | ||
| Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point | Q40324294 | ||
| Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. | Q40338396 | ||
| Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. | Q40365566 | ||
| Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. | Q40532403 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | lymphocyte | Q715347 |
| P304 | page(s) | 1924 | |
| P577 | publication date | 2017-10-31 | |
| P1433 | published in | F1000Research | Q27701587 |
| P1476 | title | Recent therapeutic advances in chronic lymphocytic leukemia | |
| P478 | volume | 6 |
| Q97524840 | Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents |
| Q59137904 | Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia |
| Q90389794 | Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia |
Search more.